[Clinical trials of neo-adjuvant chemotherapy for advanced gastric cancer with peritoneal dissemination].
Since 2000, we have introduced pre-operative chemotherapy including intra-peritoneal chemotherapy to patients with positive cytology and with no non-curative factors except peritoneum. Since 2006, we have started phase I trial with S-1 and intra-peritoneal chemotherapy with docetaxel to improve the efficacy and safety of the pre-operative regimen for advanced gastric cancer with peritoneal dissemination. The combination therapy with local and systemic chemotherapy is a promising regimen for gastric cancer with peritoneal dissemination.
Fujiwara
Yoshiyuki
Y
Dept. of Gastroenterological Surgery, Graduate School of Medicine, Osaka University.
Takiguchi
Shuji
S
Nakajima
Kiyokazu
K
Miyata
Hiroshi
H
Yamazaki
Makoto
M
Nishida
Toshiro
T
Doki
Yuichiro
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid